Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX OLE for Platysma Prominence
NCT05134649Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of botulinum toxin type A in platysma prominence, sponsored by AbbVie Inc.. Started Nov 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
platysma prominence
Beyond the preview
Go deeper on NCT05134649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134649.